Previous close | 0.8000 |
Open | 0.8000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 1.00 |
Expiry date | 2024-10-18 |
Day's range | 0.8000 - 0.8000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
VIENNA, Va., May 08, 2024--CEL-SCI receives FDA go-ahead for its confirmatory study of Multikine in the treatment of head & neck cancer.
VIENNA, Va., April 23, 2024--CEL-SCI appoints Mario Gobbo to its Board of Directors.
VIENNA, Va., March 19, 2024--CEL-SCI’s LEAPS vaccine offers promising new paradigm to treat rheumatoid arthritis: published in Frontiers in Immunology.